Condition: Type 2 Diabetes · Obese · Overweight · Sponsor: Golo
The objective of this study is to investigate the efficacy and safety of the GOLO for Life® Plan (G4LP) and Release supplementation on glycemic control and weight in overweight and obese adults with Prediabetes or Type 2 Diabetes. The change in glycemic control from baseline at Days 90 and 180 following the G4LP and supplementation with Release will be assessed. Additionally, the safety and tolerability of the G4LP and Release supplementation will be measured by the occurrence of and/or changes in pre-emergent and post-emergent adverse events (AEs).
This description comes directly from the study's public registry record.
Marc Moulin, PhD · 1-226-781-9094 · mmoulin@kgkscience.com
KGK Science Inc. · participate@kgkscience.com
Always discuss trial participation with your own doctor first.
| One Retreat Wellness | LaSalle, Ontario, Canada | Recruiting |
| KGK Science Inc. | London, Ontario, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05844644